FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:583-584 August 19, 1993 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Headache during or after intravenous immune globulin infusion is a common side effect of this increasingly frequent treatment. Headache usually occurs with initial infusions, particularly when they are administered at fast rates, but may recur even with slower subsequent infusions. Frequently, these headaches are palliated with acetaminophen and diphenhydramine. Aseptic meningitis has been associated with recurrent intravenous-immune globulin-associated headaches^1,2,3. We report on a patient in whom migraine developed after his first intravenous immune globulin treatment. Migraine recurred after the second treatment, and propranolol prevented subsequent treatment-associated headaches.

A 45-year-old man had chronic inflammatory demyelinating polyradiculoneuropathy without . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]